Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 280

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Impact of Interferon Alfa–2B and Ribavirin on Progression of Liver Fibrosis in Patients With Chronic Hepatitis C

Open access
Poynard, Thierry, McHutchison, John, Davis, Gary L., Esteban-Mur, Rafael, Goodman, Zachary, Bedossa, Pierre, Albrecht, Janice·2000·Hepatology

Abstract

The extent of liver fibrosis is an important prognostic factor in patients infected with hepatitis C virus. Administration of a combination of interferon and ribavirin produces a superior viral clearance response rate than interferon alone. The effect of this combination regimen on hepatic fibrosis has not been established. To determine the impact of combination regimen or interferon alone on the progression of liver fibrosis we pooled individual data of 1,509 patients with pretreatment and post–treatment biopsies from 3 randomized trials. Fibrosis progression and regression rates between biopsies were calculated by the Kaplan–Meier method and by the fibrosis progression rate per year. The percentage of patients without significant fibrosis (stage 0 or 1) at 96 weeks was 68 ± 4% (mean ± SE) when treated by combination regimen for 48 weeks, 64 ± 4% by interferon alone for 48 weeks, 42 ± 7% by combination regimen for 24 weeks (lower than both 48–week regimens P < .001), and 24 ± 9% interferon alone for 24 weeks (lower than the combination regimen for 24 weeks; P = .02). Three factors were independently associated with fibrosis reduction: sustained viral response, duration of treatment, and baseline fibrosis stage (all P < .001 in proportional hazards regression model). These results show that interferon and ribavirin combination therapy significantly reduces the rate of fibrosis progression in patients with hepatitis C. This effect was most prominent in patients who achieved a virologic response, those receiving 48 weeks of therapy, and in patients with significant fibrosis at baseline.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/jhep.2000.19347

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 280

Metadata

Authors
Poynard, T., McHutchison, J., Davis, G. L., Esteban-Mur, R., Goodman, Z., Bedossa, P., & Albrecht, J.
Venue
Hepatology
Published
2000-11
Volume
32
Issue
5
Pages
1131-1137
ISSN
0270-9139 (ISSN-L)
OpenAlex
W1999092338
Cited by
280
References
22
FWCI
20.19
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of Interferon Alfa–2B and Ribavirin on Progression of Liver Fibrosis in Patients With Chronic Hepatitis C. https://app.cochat.ai/papers/10.1053/jhep.2000.19347
The paper
Poynard, T., McHutchison, J., Davis, G. L., Esteban-Mur, R., Goodman, Z., Bedossa, P., & Albrecht, J. (2000). Impact of Interferon Alfa–2B and Ribavirin on Progression of Liver Fibrosis in Patients With Chronic Hepatitis C. Hepatology. https://doi.org/10.1053/jhep.2000.19347

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.